Nearly $400 million dollars has recently flooded into the coffers of psychedelic drug companies. That's enough capital to power a lot of growth.
Psychedelics
Oregon wants experts for new psilocybin-assisted therapy board
Oregon’s effort to create a new psilocybin-assisted therapy system has attracted attention from across the country.
Mind Cure Announces Eligibility for DTC Trading
Mind Cure stock is now much more easily accessible for U.S.-based investors.
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
Numinus' Vancouver clinic will be used for collaboration on a clinical trial with MAPS for MDMA-assisted therapy for PTSD.
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021
Entheon announces an agreement for the purpose of conducting a Phase 1 clinical trial.
The Psychedelics Revolution: It’s No Longer BAD To Feel GOOD
A Psychedelic Drug Revolution is occurring -- to bring badly needed psychedelic medicines to a world suffering from a Mental Health Crisis.
Entheon Biomedical to Begin Trading on the Frankfurt Exchange
Entheon adds a German listing to its original CSE listing.
MindMed Announces 2nd $25 Million Bought Deal Public Offering
MindMed's most recent financing is at nearly double where it priced units just 6 weeks earlier.
MindMed Upsizes Previously Announced Bought Deal Public Offering
MindMed's CAD$25-million bought deal financing becomes a $30 million financing -- the same day.
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
MindMed launches its digital medical division.
Why An ATAI IPO Is Driving MindMed Stock
ATAI Life Sciences is going public. MindMed Inc is hitting new highs. The two events ARE connected.
Novamind Closes Oversubscribed CAD$10 Million Private Placement
Novamind has closed on double its original target (CAD$5 million). Preparing to commence trading on the CSE (symbol "NM").
ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round
With ATAI eying a Spring 2021 IPO, it announces a $125 million private equity financing for Series C.
Mind Cure Sits With $5 Million Cash And Value-Priced For Investors
Mind Cure Health just cashed up. Mind Cure's share price has recently slid. Buying opportunity.
PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform
Revive Therapeutics and PharmaTher are teaming up to research the potential of psilocybin as a cancer treatment.